ClearPoint Neuro (NASDAQ:CLPT – Get Free Report) announced its quarterly earnings results on Wednesday. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.04), Zacks reports. The firm had revenue of $12.13 million during the quarter, compared to the consensus estimate of $11.97 million. ClearPoint Neuro had a negative net margin of 69.08% and a negative return on equity of 122.17%.
Here are the key takeaways from ClearPoint Neuro’s conference call:
- ClearPoint Neuro reported record Q1 2026 revenue of $12.1 million, up 43% year over year, with 16% organic growth driven by its core device businesses and the newly added IRRAflow line.
- Gross margin improved to 64% from 60% a year ago, helped by lower excess and obsolete inventory reserves and early benefit from the IRRAS integration.
- The company reaffirmed full-year 2026 revenue guidance of $52 million to $56 million and said sequential growth should continue through the rest of the year, though first-half timing may be uneven.
- Management highlighted progress across all four growth pillars, including new CAL facility studies, the first Asia-Pacific commercial drug delivery procedure, and expansion of the 3.x navigation platform into Europe and Canada.
- ClearPoint said it has successfully integrated IRRAflow operations and expects the business to become cash neutral as early as 2027, supported by cost synergies, facility consolidation, and broader commercial adoption.
ClearPoint Neuro Trading Up 10.4%
Shares of NASDAQ CLPT traded up $1.27 during trading on Thursday, reaching $13.46. The company had a trading volume of 575,601 shares, compared to its average volume of 724,050. ClearPoint Neuro has a 12 month low of $8.27 and a 12 month high of $30.10. The company has a quick ratio of 5.13, a current ratio of 5.91 and a debt-to-equity ratio of 1.75. The stock has a market cap of $403.61 million, a P/E ratio of -14.72 and a beta of 1.29. The company’s fifty day moving average price is $10.36 and its 200-day moving average price is $13.36.
Wall Street Analyst Weigh In
Get Our Latest Research Report on ClearPoint Neuro
Institutional Trading of ClearPoint Neuro
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd bought a new stake in shares of ClearPoint Neuro in the 4th quarter valued at $25,000. BNP Paribas Financial Markets lifted its holdings in ClearPoint Neuro by 2,435.2% in the second quarter. BNP Paribas Financial Markets now owns 2,231 shares of the company’s stock valued at $27,000 after buying an additional 2,143 shares during the period. Legal & General Group Plc bought a new stake in ClearPoint Neuro during the second quarter valued at $35,000. Russell Investments Group Ltd. boosted its position in ClearPoint Neuro by 1,079.0% during the third quarter. Russell Investments Group Ltd. now owns 2,358 shares of the company’s stock valued at $51,000 after acquiring an additional 2,158 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in ClearPoint Neuro during the 2nd quarter worth about $80,000. Institutional investors and hedge funds own 30.08% of the company’s stock.
About ClearPoint Neuro
ClearPoint Neuro, Inc is a medical technology company specializing in the development and commercialization of an MRI-guided therapy platform for minimally invasive neurosurgical procedures. Headquartered in Cambridge, Massachusetts, the company’s flagship ClearPoint® SmartFrame™ system enables surgeons to perform accurate and efficient intracranial interventions by providing real-time magnetic resonance imaging feedback. This technology is designed to improve patient safety and outcomes in treatments ranging from deep brain stimulation electrode placement to laser ablation of epileptic foci and brain tumors.
The ClearPoint System integrates hardware, software and imaging capabilities to guide instruments through the brain with submillimeter precision.
Featured Stories
- Five stocks we like better than ClearPoint Neuro
- Cisco’s Vertical Rally May Still Be in the Early Innings
- Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now
- The Great SPR Arbitrage: An Oil Market Glitch Fuels Sector Gains
- Why Satellogic Could Be One of the Biggest Space Winners of 2026
Receive News & Ratings for ClearPoint Neuro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ClearPoint Neuro and related companies with MarketBeat.com's FREE daily email newsletter.
